{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse:00424:b retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Ahse%3A00424%3Ab",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001552,
    "timestamp_received": "2026-11-09T16:12:53.701518Z",
    "timestamp_returned": "2026-11-09T16:12:53.703070Z",
    "trace_id": "e226ca12-16ea-4416-a910-968da579fb5a"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:hse:00424:b",
      "type": "Indication",
      "description": "Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2026-08-02:0",
          "type": "Contribution",
          "description": "Initial curation of into moalmanac-db",
          "date": "2026-08-02",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:hse:2019-05-01:0",
          "type": "Contribution",
          "description": "Indication approved for reimbursement.",
          "date": "2019-05-01",
          "contributor": {
            "id": "agent:org:hse",
            "type": "Agent",
            "agentType": "organization",
            "name": "Health Service Executive",
            "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hse:00424",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Obinutuzumab and Bendamustine Therapy - 28 day cycle. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "Obinutuzumab and Bendamustine Therapy - 28 day cycle, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8392/424_Obinutuzumab_and_Bendamustine.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/8392/424_Obinutuzumab_and_Bendamustine.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2017-10-10",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2026-03-06",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The Republic of Ireland's Health Service Executive (HSE) has approved obinutuzumab in combination with bendamustine for reimbursement as a treatment option for the treatment of patients with previously untreated advanced follicular lymphoma. The treatment regimen describes eligibility criteria separately for use within the first and second line of treatment. In a first line setting, patients must have previously untreated, CD20-positive follicular lymphoma (grade 1 to 3a) with advanced disease (stage III, stage IV, or stage II with bulk disease [tumor >= 7 cm in the greatest dimension]), ECOG status 0-2, and adequate hematological, renal, and liver status. In the second line setting, patients must have CD20-positive indolent non-Hodgkin lymphoma refractory to rituximab, ECOG 0-2 (ECOG 3 at the discretion of the treating clinician), and adequate hematological, renal, and liver status.",
          "description": "The description text for all Statements derived from this Indication."
        },
        {
          "name": "reimbursement_scheme",
          "value": "ODMS",
          "description": "Current scheme used to reimburse indication."
        },
        {
          "name": "reimbursement_comment",
          "value": null,
          "description": "More details about the current reimbursement scheme(s)."
        }
      ]
    }
  ]
}